Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
992-21-2
Molecular formula
C29H38N4O10
Molecular weight
602.6 g/mol
Drug class
Tetracycline-class antibacterial antibiotic
Mechanism of action
Bacteriostatic agent that binds the bacterial 30S ribosomal subunit and prevents aminoacyl-tRNA access to the mRNA–ribosome complex, inhibiting protein synthesis. In acne, part of the effect is due to reduced growth of susceptible skin organisms and reduced free fatty acids in sebum.
Indications / reported uses
Moderate-to-severe acne vulgaris
Infections caused by tetracycline-sensitive organisms, including selected respiratory, urogenital (Chlamydia), soft-tissue and rickettsial infections; use is subject to official antimicrobial guidance and product-specific indication
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Lymecycline PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Lymecycline Permitted Daily Exposure (PDE) report (the Lymecycline PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Lymecycline Occupational Exposure Limit (OEL) report (the Lymecycline OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.